Description: Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HER2-Expressing Solid Tumors
Mechanism of Action: Immune stimulating antibody drug conjugate – trastuzumab like antibody conjugated to a TLR7/8 payload. Currently combination with Pembrolizumab.
Target Patient Population: Advanced solid tumor patients with IHC 2+/3+/or Her2 amp on NGS/FISH/CISH.
Study Design: Study Drug will be administered IV every 3 weeks.